Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Sep;7(9):494-509.
doi: 10.1038/nrurol.2010.134.

Therapeutic targeting of the prostate cancer microenvironment

Affiliations
Review

Therapeutic targeting of the prostate cancer microenvironment

Maria Karlou et al. Nat Rev Urol. 2010 Sep.

Abstract

Solid tumors can be thought of as multicellular 'organs' that consist of a variety of cells as well as a scaffold of noncellular matrix. Stromal-epithelial crosstalk is integral to prostate cancer progression and metastasis, and androgen signaling is an important component of this crosstalk at both the primary and metastatic sites. Intratumoral production of androgen is an important mechanism of castration resistance and has been the focus of novel therapeutic approaches with promising results. Various other pathways are important for stromal-epithelial crosstalk and represent attractive candidate therapeutic targets. Hedgehog signaling has been associated with tumor progression, growth and survival, while Src family kinases have been implicated in tumor progression and in regulation of cancer cell migration. Fibroblast growth factors and transforming growth factor beta signaling regulate cell proliferation, apoptosis and angiogenesis in the prostate cancer microenvironment. Integrins mediate communication between the cell and the extracellular matrix, enhancing growth, migration, invasion and metastasis of cancer cells. The contribution of stromal-epithelial crosstalk to prostate cancer initiation and progression provides the impetus for combinatorial microenvironment-targeting strategies.

Trial registration: ClinicalTrials.gov NCT00321646 NCT00348998 NCT00631527 NCT01163084.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Oncogene. 2004 Mar 18;23(12):2197-205 - PubMed
    1. Cancer Res. 2006 Aug 15;66(16):8007-16 - PubMed
    1. Cancer Res. 2000 Jun 1;60(11):3031-8 - PubMed
    1. Lancet. 2002 Jul 13;360(9327):103-6 - PubMed
    1. Clin Exp Metastasis. 2003;20(5):413-20 - PubMed

Associated data